Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Capital Expenditures data on record, last reported at $11000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 375.0% year-over-year to $11000.0; the TTM value through Dec 2025 reached $296000.0, up 64.44%, while the annual FY2025 figure was $607000.0, 237.22% up from the prior year.
  • Capital Expenditures reached $11000.0 in Q4 2025 per CCCC's latest filing, down from $302000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $4.0 million in Q4 2022 and bottomed at -$1.8 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $527882.4, with a median of $196000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: soared 29300.0% in 2021, then plummeted 255.39% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $109000.0 in 2021, then soared by 3607.34% to $4.0 million in 2022, then plummeted by 96.11% to $157000.0 in 2023, then crashed by 102.55% to -$4000.0 in 2024, then soared by 375.0% to $11000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $11000.0 in Q4 2025, $302000.0 in Q3 2025, and -$4000.0 in Q4 2024.